CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced the appointment of Mark A. Klausner, M.D. as Chief Medical Officer (“CMO”). Dr. Klausner has over 25 years of significant pharmaceutical experience spanning many functional and therapeutic areas, including extensive experience in the nephrology and cardiovascular therapeutic areas.
Dr. Klausner joins CorMedix from Nephrogenex, Inc. a developmental-stage biotechnology company, where he held the position of Chief Medical Officer since 2007. Dr. Klausner was responsible for the strategy and execution of Nephrogenex’s clinical trials and regulatory compliance, including its submissions and correspondence with the Food and Drug Administration (“FDA”). Previous to Nephrogenex, Dr. Klausner held various vice presidential roles at Johnson & Johnson (“J&J”) since 1990, in the areas of medical affairs, clinical R&D, and domestic and global drug safety and surveillance. Before joining J&J, Dr. Klausner held director positions at Wyeth Pharmaceuticals in the areas of cardiovascular clinical research and OTC clinical research since 1987. Prior to his pharmaceutical experience, Dr. Klausner was a member of a private practice, multi-specialty internal medicine group where he was one of two nephrologists with responsibilities for an outpatient dialysis center, in-hospital dialysis and nephrology consultations, and an office-based practice.
Dr. Klausner has been involved in several New Drug Applications and supplemental New Drug Applications. While at J&J, he was the lead company presenter at two public FDA Advisory Committee meetings resulting in new drug approvals. Dr. Klausner holds board certifications in nephrology and internal medicine. Dr. Klausner received his medical degree from Harvard Medical School. He completed his internship in Internal Medicine at Columbia Presbyterian Hospital in New York City and then returned to Harvard to complete his Internal Medicine residency and nephrology fellowship at Beth Israel Hospital in Boston. He has had extensive interactions with the nephrology community and regulatory bodies and has authored numerous publications in peer-reviewed medical journals.